Small Business Global Trade Award from World Trade Week NY 2016


This week, Target Health received the Small Business Global Trade Award from WORLD TRADE WEEK NYC 2016. The award was presented to Dr. Jules T. Mitchel, President of Target Health by Nancy Ploeger, International Women’s Entrepreneurial Challenge Foundation, and Maria Torres-Springer, President and CEO of the New York City Economic Development Corporation (NYCEDC).



ON TARGET is the newsletter of Target Health Inc., a NYC – based, full – service, contract research organization (eCRO), providing strategic planning, regulatory affairs, clinical research, data management, biostatistics, medical writing and software services to the pharmaceutical and device industries, including the paperless clinical trial.


For more information about Target Health contact Warren Pearlson (212-681-2100 ext. 165). For additional information about software tools for paperless clinical trials, please also feel free to contact Dr. Jules T. Mitchel or Ms. Joyce Hays. The Target Health software tools are designed to partner with both CROs and Sponsors. Please visit the Target Health Website.


Joyce Hays, Founder and Editor in Chief of On Target

Jules Mitchel, Editor



Filed Under News | Leave a Comment



Podiatric Surgery – by © Photographer – James C. Mutter / Podiatrist Kamran Jamshidinia, MD /, CC BY-SA 3.0,



Podiatry or podiatric medicine is a branch of medicine devoted to the study of, diagnosis, and medical and surgical treatment of disorders of the 1) ___, ankle and lower extremity. The term podiatry came into use in the early 20th century in the United States and is now used worldwide, including countries such as the United Kingdom and Australia. Podiatry is practiced as a specialty in many countries, while in many English-speaking countries, the older title of 2) ___ may be used by some clinicians (not to be confused with chiropractic, which is unrelated). In Australia, the title is podiatrist or podiatric physician and the specialist is the podiatric surgeon. In many non-English-speaking countries of Europe, the title used may be podologist or podologo. The level and scope of the practice of podiatry vary among countries.


According to the American Association of Colleges of Podiatric Medicine, a Doctor of Podiatric Medicine (DPM) is a medical specialist who diagnoses and treats conditions affecting the foot, ankle, and structures of the 3) ___leg. The US podiatric medical school curriculum includes lower extremity anatomy, general human anatomy, physiology, general medicine, physical assessment, biochemistry, neurobiology, pathophysiology, genetics and embryology, microbiology, histology, pharmacology, women’s health, physical rehabilitation, sports medicine, research, ethics and jurisprudence, biomechanics, general principles of orthopedic surgery, and foot and ankle surgery. US trained podiatrists rotate through major areas of medicine during residency, including emergency medicine, orthopedic surgery, general surgery, anesthesia, radiology, pathology, infectious disease, endocrinology, sports medicine, physical therapy, biomechanics, geriatrics, internal medicine, critical care, cardiology, vascular surgery, psychiatric and behavioral health, neurology, pediatrics, dermatology, pain management, wound care and primary care.


In the United States, medical and surgical care of the foot and ankle is mainly provided by two groups of physicians: podiatrists (Doctor of Podiatric Medicine or DPM) and 4) ___ surgeons (MD or DO). The first year of podiatric medical school is similar to training that M.D. and DO. students receive, but with an emphasized scope on foot, ankle, and lower extremity. Being classified as a second entry degree, in order to be considered for admission an applicant must first complete a minimum of 90 semester hours at the university level or more commonly, complete a bachelor’s degree with emphasis on general/organic chemistry, biochemistry, biology, etc. In addition, potential students are required to take the MCAT, which stands for, 5) ___ ___ ___. The DPM degree itself takes a minimum of four years to complete. The four-year podiatric medical school is followed by a surgical based residency, which is hands-on post-doctoral training. There are two standard residencies: Podiatric Medicine & Surgery 24 and Podiatric Medicine & Surgery 36 (PM&S 24 or PM&S 36). These represent the two- or three-year residency training. As of, July 2013, all residency programs in podiatry are required to transition to a minimum three-years of post-doctoral training.


Upon completion of their residency, podiatrists can decide to become board certified by a number of specialty boards including the more common American Board of Podiatric Medicine and/or the American Board of Podiatric Surgery. The ABPMS or The American Board of Podiatric Medical Specialties has been certifying podiatrists since 1998. Within the American Board of Podiatric Surgery, PM&S 24 graduates can sit for Board Certification in Foot 6) ___Surgery and those that complete PM&S 36 can sit for Board Certification in Foot Surgery and Board Certification in Reconstructive Rearfoot & Ankle Surgery. Both boards in ABPS are examined as separate tracks. Though the ABPS and ABPM are more common, other boards are equally challenging and confer board qualified/certified status. Fellowship training is available after residency in such fields such as geriatrics, foot and ankle traumatology, infectious disease etc. In reality though, the residency training of most podiatry residencies today are already highly inclusive of these medical areas.


Podiatrists certified by the ABPS have successfully completed an intense board certification process comparable to that undertaken by individual MD and DO specialties. There are two surgical certifications under ABPS. They are Foot Surgery and Reconstructive Rearfoot/Ankle (RRA) Surgery. In order to be Board Certified in RRA, the sitting candidate has to have already achieved board certification in Foot Surgery. Certification by ABPS requires initial successful passing of the written examination. Then the candidate is required to submit surgical logs indicating experience and variety. Once accepted, the candidate has to successfully pass oral examination and computer questions of clinical simulation. While the majority of podiatric physicians are in solo practice, there has been a movement toward larger group practices as well as the use of podiatrists in multi-specialty groups including orthopedic groups, treating the effects of a disease like 7) ___, on feet, or in multi-specialty orthopedic surgical groups. Some podiatrists work within clinic practices such as the Indian Health Service (IHS), the Rural Health Centers (RHC) and Community Health Center (FQHC) systems established by the US government to provide services to under-insured and non-insured patients as well as within the United States Department of Veterans Affairs providing care to veterans of military service. Some podiatrists have primarily surgical practices. Some specialists complete additional fellowship training in reconstruction of the foot and ankle from the effect of diabetes or physical trauma. Other surgeons practice minimally invasive percutaneous surgery for cosmetic correction of hammer 8) ___ and bunions. Podiatrists utilize medical, orthopedic, biomechanical and surgical principles to maintain and correct foot deformities. Podiatrists may also be able to be a Chief of Surgery in a public or private hospital. Podiatrists use 9) ___laser products for plantar warts, neuromas, in- grown toe nails and for the ablation, vaporization and coagulation of soft tissue among other uses.


ANSWERS: 1) Foot; 2) chiropodist; 3) leg; 4) orthopedic; 5) Medical College Admission Test; 6) Surgery; 7) diabetes; 8) toes; 9) laser


William M. Scholl MD


William M. Scholl MD (1882-1968)


William M. Scholl (June 22, 1882 – March 30, 1968) was a pioneer of foot care and the founder of Dr. Scholl’s, a brand of foot care products. Scholl was born in La Porte, Indiana, one of 13 children. His parents were dairy farmers, his grandfather was a cobbler. His first job was at a shoemaker’s shop in Michigan City, Ind. Scholl came to Chicago in 1899 and worked at Rupert’s Shoe Store on East Harrison Street. Scholl studied medicine at Loyola University Chicago. During his studies, while working in a shoe store in the evenings, he became interested in podiatry. He graduated from Illinois Medical College (which later became part of Loyola University) in 1904.


In 1904, Scholl invented and patented an arch support and founded Dr. Scholl’s in order to sell it. He was joined by his brother Frank who directed the company’s overseas business, establishing Scholl Manufacturing Company, Ltd. in London in 1910. Three years later, after patenting some products to ease foot pain, he incorporated the Scholl Manufacturing Co., where the motto was “Early to bed, early to rise, work like hell and advertise!“ In 1912, he started the Illinois College of Chiropody and Orthopedics, located at 1321 N. Clark St. in Chicago. Scholl taught there, performed clinical work and financed the operation of the school until it was taken over by a non-profit corporation. Scholl went on to develop more than 1,000 foot aids. These included a silver clip designed in 1946 to treat ingrown toenails. While too soft to have much of a corrective effect and difficult to apply, it inspired later steel clip designs. Scholl practiced medicine in Chicago from 1905 until 1946 while also directing his company. He continued to serve as the company’s President and chief executive officer until March 1968, when he was elected Chairman of the Board. He worked in that capacity until his death. He left the bulk of his estate to the Dr. Scholl Foundation which he had established in 1947.


Scholl never married. His brother Frank, who had helped set up the original company, had sons who were doctors and were involved in the company and foot care. The William Scholl College of Podiatric Medicine at Dearborn and Oak Streets is not just a school, it’s the heart of an effort to make sure everyone has healthy feet, regardless of how much money they have or where they live. In 2001 the college merged with Finch University of Health Sciences/The Chicago Medical School. Most classroom and lab activities have relocated to Finch’s campus in suburban North Chicago. Here there is a teaching clinic where supervised students trim calluses and file toenails for $15. There’s also another clinic where the students and doctors offer free services from checkups to surgery for the uninsured and an award-winning program that takes students to homeless shelters around the city. Recently a new free clinic has opened to treat the foot problems connected to diabetes. More than 2,000 patients are treated courtesy of the Scholl College each year. “We’re the only source of foot care for a lot of people,“ said Dr. Philip Gianfortune, chairman of Scholl’s department of medicine and an alumnus, class of 1982. “We keep the senior citizens independent and the working poor working, so they don’t get unemployed or homeless,“ he said. “It’s part of our mission to educate students as well as treat those in need.“ We check reflexes and circulation, clip nails, ask about medical problems and medications and talk to about home, family and life in general.


The college changed names several times over the years, to reflect the changing language of the profession. It became the Scholl College of Podiatric Medicine in 1986. (The school is not affiliated with Shearing-Plough, which now owns the Scholl product company, although Shearing-Plough has been generous with donations.) The school expanded to 1327 N. Clark St. and remained there until 1973, when it hopped to its current home at 1001 N. Dearborn St. The building also houses the Foot and Ankle Clinics of America’s Gold Coast location, where supervised students can treat patients. Constructed in 1928, the building had been home to the Harriet W. McCormick YWCA and there are still elements of those grand old days. Just off the clean, modern lobby is the building’s original entryway. Here, the ceiling is a beautiful gold dome. The floors are marble and the walls are covered with elegant tiles, design elements from an earlier time. A large part of the patient population is based in the inner city. Making sure the most patients get the best services is important to the students and their instructors who started a foot-care program for the homeless, a program that would go to shelters. It’s essential for the homeless to remain ambulatory to seek adequate care, shelter and possible employment. This program, with the help of the Illinois Podiatric Medical Association, became a reality on a national level. Teams of traveling students and instructors examine feet, cut nails, give out socks and construct foam sheaths to protect hurt toes. Depending on circumstances, they may treat anything from frostbite to gunshot wounds to foot and ankle ulcers. Scholl doctors also have collected data from their shelter patients to determine the most serious problems faced by the homeless and to develop treatment plans.


The Illinois Department of Public Health, the U.S. Public Health Service and Department of Health and Human Services have given the program several awards and schools around the nation call Scholl for advice in setting up their own versions. Over the years, the college has “shared soles“ with the needy in the form of giant shoe drives. More than 150,000 pairs of shoes have been donated and more come in all the time. Shoe stores going out of business, donate to shelters and clinics, through the Scholl program. The William Scholl College of Podiatric Medicine teaching clinic operates Tuesdays and Thursdays from 8:30 a.m to 1:30 p.m. The clinic for the uninsured operates Tuesdays and Thursdays from 2:30 to 6:30 p.m. For information, call the Foot and Ankle Clinics of America’s Gold Coast location at 312-280-7886 or the college at 312-280-2880.


Americans don’t pay enough attention to the care of their feet. We rarely recommend physicians, however about a year ago we did give the name of an outstanding endodontist here in Manhattan, and with this publication we can recommend another outstanding doctor, podiatrist, Dr. Jennifer McCoy at 1125 Park Avenue.



Filed Under News | Leave a Comment

Increased Physical Activity Associated with Lower Risk of 13 Types of Cancer


Hundreds of previous studies have examined associations between physical activity and cancer risk and shown reduced risks for colon, breast, and endometrial cancers; however, results have been inconclusive for most cancer types due to small numbers of participants in the studies. A new study was recently published online in JAMA Internal Medicine (16 May 2016) showed that greater levels of leisure-time physical activity were associated with a lower risk of developing 13 different types of cancer. The risk of developing seven cancer types was 20% (or more) lower among the most active participants (90th percentile of activity) as compared with the least active participants (10th percentile of activity). The study pooled data on 1.44 million people, ages 19 to 98, from the United States and Europe, and was able to examine a broad range of cancers, including rare malignancies. Participants were followed for a median of 11 years during which 187,000 new cases of cancer occurred.


The study confirmed that leisure-time physical activity, as assessed by self-reported surveys, was associated with a lower risk of colon, breast, and endometrial cancers. They also determined that leisure-time physical activity was associated with a lower risk of 10 additional cancers, with the greatest risk reductions for esophageal adenocarcinoma, liver cancer, cancer of the gastric cardia, kidney cancer, and myeloid leukemia. Myeloma and cancers of the head and neck, rectum, and bladder also showed reduced risks that were significant, but not as strong. Risk was reduced for lung cancer, but only for current and former smokers; the reasons for this are still being studied.


Leisure-time physical activity is defined as exercise done at one’s own discretion, often to improve or maintain fitness or health. Examples include walking, running, swimming, and other moderate to vigorous intensity activities. The median level of activity in the study was about 150 minutes of moderate-intensity activity per week, which is comparable to the current recommended minimum level of physical activity for the U.S. population.


There are a number of mechanisms through which physical activity could affect cancer risk. It has been hypothesized that cancer growth could be initiated or abetted by three metabolic pathways that are also affected by exercise: estrogens and androgens; insulin and insulin-like growth factors; and proteins involved with both insulin metabolism and inflammation. Additionally, several non-hormonal mechanisms have been hypothesized to link physical activity to cancer risk, including inflammation, immune function, oxidative stress, and, for colon cancer, a reduction in time that it takes for waste to pass through the gastrointestinal tract. Most associations between physical activity and lower cancer risk changed little when adjusted for body mass index, suggesting that physical activity acts through mechanisms other than lowering body weight to reduce cancer risk. Associations between physical activity and cancer were also similar in subgroups of normal weight and overweight participants, and in current smokers or people who never smoked.


Investigational Malaria Vaccine Protects Healthy U.S. Adults for More than One Year


The parasites that cause malaria are transmitted to humans through the bite of an infected mosquito. The PfSPZ Vaccine is composed of live, but weakened P. falciparum sporozoites — the early developmental form of the parasite. Previous research showed the PfSPZ Vaccine to be highly protective three weeks after immunization.


According to an article published online in Nature Medicine (9 May 2016), an experimental malaria vaccine protected a small number of healthy, malaria-naive adults in the United States from infection for more than one year after immunization. The vaccine, known as the PfSPZ Vaccine, was developed and produced by Sanaria Inc., of Rockville, Maryland, with support from several Small Business Innovation Research (SBIR) awards from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. NIAID researchers and collaborators at the University of Maryland School of Medicine in Baltimore, conducted the clinical evaluation of the vaccine, which involved immunization and exposing willing healthy adults to the malaria-causing parasite Plasmodium falciparum (P. falciparum) in a controlled setting.


The Phase 1 trial took place at the NIH Clinical Center in Bethesda, Maryland, and at the University of Maryland Medical Center and enrolled 101 healthy adults aged 18 to 45 years who had never had malaria. Of these volunteers, 59 received the PfSPZ Vaccine; 32 participants served as controls and were not vaccinated. Vaccine recipients were divided into several groups to assess the roles of the route of administration, dose, and number of immunizations in conferring short- and long-term protection against malaria.


To determine if the number of immunizations influenced protection, vaccinated participants received either three (nine participants) or four (28 participants) intravenous (IV) immunizations of the PfSPZ Vaccine at a higher dose than tested in previous human studies. To compare the protective efficacy of different routes of administration, eight participants received four immunizations via intramuscular injection (IM) at a dose approximately 10-fold higher than the dose administered intravenously. This was done to help the research team assess if IV administration was necessary and more efficient based on the dose required. To evaluate how well the PfSPZ Vaccine prevented malaria infection, all participants – including the control participants who were not vaccinated — were exposed at varying times to the bites of mosquitoes carrying the same P. falciparum strain from which the PfSPZ Vaccine was derived. The Walter Reed Army Institute of Research in Silver Spring, Maryland, carried out this controlled human malaria infection procedure — a standard process in early phase malaria vaccine trials.


To assess short-term protection, participants were exposed to the bites of parasite-infected mosquitoes three weeks after receiving their final vaccination. Scientists then took blood samples from each participant to measure parasite levels for evidence of protection. For nine participants who received three IV doses, three were protected, or had no detectable parasites in their blood. For the nine participants who received four IV doses, seven were protected. Only three of the eight participants who received four IM doses were protected, indicating that IV administration afforded higher levels of protection at a lower dose. To assess long-term protection, an additional group of 11 participants received four IV doses of the investigational vaccine and were exposed to the bites of malaria parasite-infected mosquitoes 21 weeks after their final vaccination. Results showed that six of 11 participants (55%) had no detectable parasites in their blood after this exposure. Four of these six participants, plus one of the participants who received the same four doses via IV and had no parasites in the blood after exposures at three weeks and 21 weeks, were exposed to mosquito bites again at 59 weeks after their final vaccination. All five participants exposed at 59 weeks did not develop parasites in their blood, while all six unvaccinated control participants became infected with malaria parasites.


Collectively, the data showed that the PfSPZ Vaccine provided malaria protection for more than one year in 55% of people without prior malaria infection. In those individuals, the PfSPZ Vaccine appeared to confer sterile protection, meaning the individuals would be protected against disease and could not further transmit malaria. The vaccinations were also well-tolerated among participants, and there were no serious adverse events attributed to vaccination. Additional results showed that antibodies may play a role in malaria protection early after the final immunization, but inducing T cells in the liver is likely necessary for durable protection. Long-term, reliable protection is important for people who are vaccinated but not exposed to malaria for months, such as travelers and military personnel. Durable protection is also important for mass vaccination campaigns in malaria-endemic regions aimed at interrupting transmission, according to the authors.


FDA Approves New, Targeted Treatment for Bladder Cancer


Urothelial carcinoma is the most common type of bladder cancer and occurs in the urinary tract system, involving the bladder and related organs. The National Cancer Institute (NCI) estimates 76,960 new cases of bladder cancer and 16,390 deaths from the disease in 2016.


The FDA has approved Tecentriq (atezolizumab) to treat urothelial carcinoma. Tecentriq targets the PD-1/PD-L1 pathway (proteins found on the body’s immune cells and some cancer cells). By blocking these interactions, Tecentriq may help the body’s immune system fight cancer cells. Tecentriq is the first FDA-approved PD-L1 inhibitor and the latest in the broader class of PD-1/PD-L1 targeted biologics approved by the FDA in the last two years. Tecentriq is approved for the treatment of patients with locally advanced or metastatic urothelial carcinoma whose disease has worsened during or following platinum-containing chemotherapy, orwithin 12 months of receiving platinum-containing chemotherapy, either before (neoadjuvant) or after (adjuvant) surgical treatment.


The safety and efficacy of Tecentriq were studied in a single-arm clinical trial involving 310 patients with locally advanced or metastatic urothelial carcinoma. This trial measured the percentage of patients who experienced complete or partial shrinkage of their tumors (objective response rate). The study also looked at the difference in effect based on “positive“ versus “negative“ expression of the PD-L1 protein on patients’ tumor-infiltrating immune cells. In all patients, 14.8% of participants experienced at least a partial shrinkage of their tumors, an effect that lasted from more than 2.1 to more than 13.8 months at the time of the response analysis. In patients who were classified as “positive“ for PD-L1 expression, 26% of participants experienced a tumor response (compared to 9.5% of participants who were classified as “negative“ for PD-L1 expression). While patients who received Tecentriq experienced a tumor response across the study, the greater effect in those who were classified as “positive“ for PD-L1 expression suggests that the level of PD-L1 expression in tumor-infiltrating immune cells may help identify patients who are more likely to respond to treatment with Tecentriq. Therefore, today the FDA also approved the Ventana PD-L1 (SP142) assay to detect PD-L1 protein expression levels onpatients’ tumor-infiltrating immune cells and help physicians determine which patients may benefit most from treatment with Tecentriq. The most common side effects of treatment with Tencentriq were fatigue, decreased appetite, nausea, urinary tract infection, fever (pyrexia) and constipation. Tencentriq also has the potential to cause infection and serious side effects that result from the immune system effect of Tencentriq (known as “immune-mediated side effects“). These severe immune-mediated side effects involve healthy organs, including the lung, colon and endocrine system.


The FDA granted the Tecentriq application breakthrough therapy designation, priority review status and accelerated approval for this indication. These are distinct programs intended to facilitate and expedite the development and review of certain new drugs in light of their potential to benefit patients with serious or life-threatening conditions.


Tecentriq is marketed by Genentech based in San Francisco, California. The Ventana PD-L1 (SP142) assay complementary diagnostic for Tecentriq is marketed by Ventana Medical Systems, based in Tucson, Arizona.


Two Art exhibitions at the Nippon Club, New York City


The Nippon Club has hosted two exhibitions on April 20 and April 27, 2016, “ANOTHER JAPAN“ and “NEXT JAPAN“ – presented by Gallery Kasagi, a gallery based in Kanagawa (Kamakura and Yokosuka), Japan. Target Health attended both art shows and mingled with many acclaimed Japanese artists.


ANOTHER JAPAN (April 20) is an exhibition that introduced 6 active Japanese artists each of whom embrace unique concepts and pursue new styles in Japanese art. Mui Ying Kwan, Cultural Liaison from Target Health Inc., had a chance to speak to two of the artists at the reception. Goroh Saitoh is a world-renowned artist, whose experience includes heading the Executive Committee of the New York-Ground Zero Street Exhibition in 2002. He described his unique artwork that was on display, as having themes involving “Mona Lisa and home town.“ Kay Yoshiya is another artist who spoke with Ms. Kwan. She incorporates her highly imaginative, traditional Japanese art techniques with European traditions. She is a researcher of Vincent van Gogh and art of the Netherlands. Her art is called “New Renaissance“, and was influenced by both European historical art and the Japanese sensitive style.


At the exhibition of “NEXT JAPAN“ (April 27), 14 young Japanese artists who aim to represent the art world’s next generation were displayed. Additionally, there was an impressive approximation of art by Noriko Tamura, who is known as one of the most popular painters in Japan. Since drawing the huge wall painting at the hotel of Xian (China) in 1988, she has painted 61 sites, around the world. Her oil paintings and sketches were also on display at this special gallery exhibition. There was a reception for the artists after the exhibition. The Saxophone player set the right mood, he played wonderful jazz such as “In a sentimental mood“ by John Coltrane & Duke Ellington.


Target Health Inc. applauds the Nippon Club for an evening of great talent and pleasure.


Photos with captions of “Another Japan“ and “Next Japan“ -part two of Japanese artist exhibition



Nippon Club New York City: On the right is Noriko Tamura, in traditional Japanese Kimono. Next to her is Mui Ying Kwan, TargetHealth’s Cultural Liaison. This photo is set against the Impressive approximation of the real sized recreation of art by Noriko Tamura, who is known as one of the most popular painting artists in Japan, since creating the huge wall painting at the hotel of Xian (China) in 1988. ©Target Health Inc.

Nippon Club New York City: Goroh Saitoh, a world-renowned artist. His experience includes heading the Executive Committee of the New York-Ground Zero Street Exhibition in 2002. ©Target Health Inc.



Don’t ask me how I dreamed these up. If you’ve never heard of  broccolicious before, it’s because I just made up the word. So I hereby proclaim that  broccolicious are an appetizer or a wonderful side dish that would go with any entr?e. I was looking for a finger food to serve guests, that would go well with various wines. We’ve been eating variations of this, all week, as I obsessively sought the exact spices and herbs to bring this little nibble to life. ©Joyce Hays, Target Health Inc.



I tried out several cheeses in this recipe but always came back to a soy cheddar, that is dairy-free and low in calories, not to mention the shade of orange, that next to the greens, gives a certain visual satisfaction. ©Joyce Hays, Target Health Inc.





1 onion, chopped

6 to 8 fresh garlic cloves, minced

1 large potato, scrubbed, peeled, grated with large holes of grater

3 or 4 cups fresh broccoli florets (fresh not frozen); save or discard stems

1 Tablespoon Kraft Mayonnaise

1 Tablespoon extra-virgin olive oil

1/2 cup fresh parsley

1/2 cup fresh cilantro

1 teaspoon cardamom

1 teaspoon turmeric-premixed-with-black pepper

1 and 1/4 cup any orange cheddar cheese (I used soy cheddar), grated

3-5 large pinches chili flakes (you decide how spicy you want them. I used 3)

1/4 cup freshly grated parmesan cheese

Pinch kosher salt

2 eggs, lightly beaten


Topping Ingredients


Horseradish Topping


1/2 container Tofutti, room temperature

2 Tablespoons white horseradish

2 Pinches chili flakes

1 and 1/2 teaspoons fresh lemon juice



Fresh ingredients, all easily obtained. I tried using fine bread crumbs for one experiment of this recipe, but found that a simple fresh potato, instead, worked well and tasted better. ©Joyce Hays, Target Health Inc.





Rinse broccoli well and dry extremely well. You want as little moisture as possible in the food processor. While it’s drying, grate the cheese. Use any block of orange cheddar you like (there’s a huge variety out there) and grate it with a hand grater, using medium holes.




Soy cheddar (orange) grated with large holes on grater; use smaller holes to grate the parmesan. ©Joyce Hays, Target Health Inc.



Grating the one potato with a hand grater, using the large holes. ©Joyce Hays, Target Health Inc.



Chopping the garlic and onion at the same time. ©Joyce Hays, Target Health Inc.



In a skillet, add one Tablespoon extra-virgin olive oil, the chopped onion, chopped garlic, grated potato and all the spices. Stir together and cook until the onion is transparent.



Here the 1 Tablespoon of extra virgin olive oil was added to the skillet, then the garlic, onion, grated potato and all the spices. Easy as A – B – C ©Joyce Hays, Target Health Inc.



Place very dry broccoli florets (also add all herbs) in a food processor bowl and break them down in 2-3 second pulses until the broccoli is finely crumbed.



Pulsing the broccoli florets (with the herbs) in food processor. ©Joyce Hays, Target Health Inc.



Chopping together fresh parsley and cilantro. ©Joyce Hays, Target Health Inc.



In a large bowl, mix and combine broccoli crumbs, the cooked onion/potato mixture, both cheeses and salt. Add the already beaten eggs and mix everything to combine well.



Now, everything gets added to a large mixing bowl, where you combine all ingredients well. ©Joyce Hays, Target Health Inc.



Preheat oven to 400 degrees

Oil a baking sheet, or cover the baking sheet with parchment paper.

With a teaspoon, or even better a melon ball scooper, scoop out broccoli mixture, the size of a cherry tomato, and drop onto the baking sheet as if you are making broccoli biscuits. After you drop each bit of broccoli mixture, don’t push down on them; leave them in the shape they are, after you drop them on the parchment.



Because I’ve been experimenting with this recipe all week, to get the right combos of the ingredients, I also tried out various sizes. So, at the start of this recipe, there’s a larger size, and here in this photo the broccoli bites are smaller. There’s so little oil in these bites, there’s no oily residue left on fingers, if that’s the way you end up serving them. ©Joyce Hays, Target Health Inc.



Bake the broccolicious bites for about 10 to 12 minutes (at 400 degrees), until the bottoms are slightly browned. So check them after baking for, say 5 minutes. If not brown, bake a little longer. Keep your eye on these small bites, after this, so they don’t burn. Because they’re so small, they’ll burn easily and if they burn, they get charred and they’re awful, so you’ll have to throw them out and start over again. You don’t want your precious time to be wasted.



Going into the oven. The larger size was baked for about 14 minutes. This smaller size for about 11 minutes. ©Joyce Hays, TargetHealth Inc.



Out of the oven in 11 minutes. Each oven is different, so keep your eye on these little munchies. ©Joyce Hays, Target Health Inc.



Out of the oven and onto a serving platter. Serve them while they’re still warm. Be sure to offer the easy-to-make topping. It’s delicious and really adds to this recipe. ©Joyce Hays, Target Health Inc.



And, yet another platter of these tasty broccolicious munchies. I forgot to add, that eating this particular finger size, is fun. You might find that kids of any age, would eat veggies more readily, if they could use their fingers. Dip each of these yummy munchkins into the horseradish topping, and you have a mouthful worth crunching down on. Last night, we dined pretty much on these broccolicious bites and continued with our nicely chilled Pouilly-Fuisse phase. Jules had pasta with the  broccolicious. ©Joyce Hays, Target Health Inc.



The horseradish topping is simple, easy, healthy and delicious. ©Joyce Hays, Target Health Inc.



Remove the broccolicious finger food from the oven and serve immediately with the topping.

To make horseradish topping: simply mix all topping ingredients in a small bowl and serve on the table.




Sipping chilled Pouilly-Fuisse, and nibbling on  broccolicious. Not bad, eh! ©Joyce Hays, Target Health Inc.



We’re entering a Pouilly-Fuisse phase and don’t care if it’s not the usual first white wine recommended by the sommelier. In our (humble) opinion, this particular Pouilly-Fuisse (pronounced: poo-yay fwee-SAY or the way I learned it in French class at Columbia Univ, PWEE-ee fwee-SAY) is not nearly as good as the Louis Jadot, which during our new tasting phase, remains our favorite. This wine is like a chardonnay or white Burgundy. However, I like the Louis Jadot Pouilly-Fuisse much better, because although it’s a bit acidic with minerals and citrus, it’s not flinty like a dry chardonnay. I’m learning as we taste, that the Pouilly-Fuisse is more layered with a wonderful rich full-bodied flavor and therefore, more interesting than a chardonnay. Finally, fun is certainly an element in sipping wine; so as we nibble the warm  broccolicious and sip the delicious icy Louis Jadot, it’s fun for us Americans, to pronounce it: “I’ll have some PWEE-ee fwee-SAY!“



So far, this is our top choice for Pouilly-Fuisse. Get 2013 or 2014. But we still have a way to go, bottles to sip before we’re done. ©Joyce Hays, Target Health Inc.



As we travel around the U.S. and the globe, on business, we’re getting compliments on the newsletter and on the recipes from every corner of the world. It’s taken me years to discover, what many of you may already know, that sharing freely, with no thought of any return, is its own reward. I’ve learned that, this feeling of sharing what we have from our home to yours, gives a certain “high.“ Then,on top of this, at a conference, when we hear people praise the recipes, we’re soaring in a rarified atmosphere. A win-win for everyone.



From Our Table to Yours !


Bon Appetit!